BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bansal N. Use of Oral Anticoagulation for Patients with ESRD on Hemodialysis with Atrial Fibrillation: Verdict 1. Clin J Am Soc Nephrol 2016;11:2093-4. [PMID: 27797899 DOI: 10.2215/CJN.08610816] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Wetmore JB, Peng Y, Gilbertson DT, Liu J. Relation of Race, Apparent Disability, and Stroke Risk With Warfarin Prescribing for Atrial Fibrillation in Patients Receiving Maintenance Hemodialysis. Am J Cardiol 2019;123:598-604. [PMID: 30527770 DOI: 10.1016/j.amjcard.2018.11.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, Bauersachs R, Wanner C. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open 2018;8:e022690. [PMID: 30206088 DOI: 10.1136/bmjopen-2018-022690] [Cited by in Crossref: 25] [Cited by in F6Publishing: 15] [Article Influence: 6.3] [Reference Citation Analysis]
3 Jain N, Reilly RF. Clinical Pharmacology of Oral Anticoagulants in Patients with Kidney Disease. Clin J Am Soc Nephrol 2019;14:278-87. [PMID: 29802125 DOI: 10.2215/CJN.02170218] [Cited by in Crossref: 24] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]